Algiax Reports Positive Ph 2a Data for AP-325 in Neuropathic Pain
04 Feb 2025 //
BUSINESSWIRE
Algiax Expands AP-325 Neuropathic Pain Phase 2a To Europe
11 Apr 2024 //
PR NEWSWIRE
Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study
30 May 2023 //
BUSINESSWIRE